Apogee Therapeutics, Inc. (NASDAQ:APGE) CEO Sells $732,750.00 in Stock

by · The Markets Daily

Apogee Therapeutics, Inc. (NASDAQ:APGE – Get Free Report) CEO Michael Thomas Henderson sold 15,000 shares of the stock in a transaction that occurred on Wednesday, January 8th. The shares were sold at an average price of $48.85, for a total transaction of $732,750.00. Following the transaction, the chief executive officer now directly owns 1,309,487 shares of the company’s stock, valued at $63,968,439.95. This represents a 1.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Michael Thomas Henderson also recently made the following trade(s):

  • On Wednesday, December 4th, Michael Thomas Henderson sold 15,000 shares of Apogee Therapeutics stock. The shares were sold at an average price of $46.58, for a total transaction of $698,700.00.
  • On Wednesday, November 6th, Michael Thomas Henderson sold 15,000 shares of Apogee Therapeutics stock. The shares were sold at an average price of $59.22, for a total transaction of $888,300.00.

Apogee Therapeutics Stock Down 16.6 %

Apogee Therapeutics stock traded down $8.16 during trading hours on Friday, hitting $41.05. The stock had a trading volume of 1,366,016 shares, compared to its average volume of 509,403. The stock has a market capitalization of $1.85 billion, a P/E ratio of -16.96 and a beta of 2.26. Apogee Therapeutics, Inc. has a 12-month low of $30.84 and a 12-month high of $72.29. The stock’s 50-day moving average price is $48.70 and its 200-day moving average price is $48.90.

Analyst Ratings Changes

Several analysts have issued reports on APGE shares. Guggenheim reiterated a “buy” rating on shares of Apogee Therapeutics in a research note on Thursday, December 12th. Canaccord Genuity Group began coverage on shares of Apogee Therapeutics in a report on Monday, November 25th. They set a “buy” rating and a $89.00 target price on the stock. Wedbush raised their price target on shares of Apogee Therapeutics from $87.00 to $90.00 and gave the stock an “outperform” rating in a report on Monday, December 2nd. Finally, Canaccord Genuity Group started coverage on shares of Apogee Therapeutics in a research report on Monday, November 25th. They issued a “buy” rating and a $89.00 target price for the company. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $89.71.

Get Our Latest Analysis on Apogee Therapeutics

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Wellington Management Group LLP grew its position in Apogee Therapeutics by 35.7% during the third quarter. Wellington Management Group LLP now owns 4,814,400 shares of the company’s stock valued at $282,798,000 after buying an additional 1,267,451 shares during the period. Driehaus Capital Management LLC lifted its position in Apogee Therapeutics by 2.6% during the second quarter. Driehaus Capital Management LLC now owns 2,117,870 shares of the company’s stock valued at $83,338,000 after purchasing an additional 54,107 shares during the last quarter. Perceptive Advisors LLC lifted its position in Apogee Therapeutics by 2.2% during the second quarter. Perceptive Advisors LLC now owns 2,105,636 shares of the company’s stock valued at $82,857,000 after purchasing an additional 45,241 shares during the last quarter. Affinity Asset Advisors LLC lifted its position in Apogee Therapeutics by 41.2% during the second quarter. Affinity Asset Advisors LLC now owns 836,283 shares of the company’s stock valued at $32,908,000 after purchasing an additional 244,190 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of Apogee Therapeutics by 11.2% in the 3rd quarter. Geode Capital Management LLC now owns 823,839 shares of the company’s stock worth $48,401,000 after acquiring an additional 82,978 shares during the last quarter. 79.04% of the stock is owned by hedge funds and other institutional investors.

Apogee Therapeutics Company Profile

(Get Free Report)

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.

Further Reading